3DBio -Model AuriNovo -Proprietary Process Technology for Microtia Patients

A small biopsy is performed on the patient’s microtia ear remnant and sent to 3DBio’s GMP manufacturing facility. The patient’s cartilage cells are isolated from the biopsy, expanded in cell culture, and then “printed” into the shape of the patient’s normal ear using 3DBio’s proprietary innovative printing technology. The components to accomplish this comprise 3DBio’s proprietary platform, including ColVivo™, its therapeutic-grade collagen bio-ink and GMPrint™, its proprietary, clinical grade 3D-bioprinter. The newly created “ear” is then sent to the clinic and implanted into the patient in an outpatient procedure